Merck's Keytruda fails in Phase III HNSCC study

Jim Rogers

new user
Merck said that its anti-PD1 drug Keytruda (pembrolizumab) failed to meet the primary endpoint in the Phase III KEYNOTE-040 trial for previously treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). http://alph.st/b4ea1232